Biomarkers in bladder cancer

被引:43
作者
Bryan, Richard T. [1 ,2 ]
Zeegers, Maurice P. [6 ]
James, Nicholas D. [2 ,3 ,5 ]
Wallace, D. Michael A. [4 ]
Cheng, Kar Keung
机构
[1] Univ Birmingham, Bladder Canc Prognosis Programme, Sch Populat Sci, Dept Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England
[3] Univ Birmingham, CRUK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England
[4] Queen Elizabeth Hosp, Dept Urol, Birmingham B15 2TH, W Midlands, England
[5] Queen Elizabeth Hosp, Univ Hosp Birmingham NHS Fdn Trust, Birmingham B15 2TH, W Midlands, England
[6] Maastricht Univ, Nutr & Toxicol Res Inst, Cluster Genet & Cell Biol, Dept Complex Genet, Maastricht, Netherlands
关键词
biomarkers; molecular markers; bladder cancer; TRANSITIONAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; SYSTEMIC INFLAMMATORY RESPONSE; FGFR3 MUTATION STATUS; 20; MESSENGER-RNA; REAL-TIME PCR; URINARY-BLADDER; RADICAL CYSTECTOMY; PROTEIN EXPRESSION; VOIDED URINE;
D O I
10.1111/j.1464-410X.2009.08880.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Detailed molecular insights into bladder cancer biology might allow more detailed prognostication and optimization of treatment with the objective of improving patient outcome and quality of life. However, in bladder cancer research the search for biomarkers has been called into question and has even obtained notoriety. It is unlikely that any single marker will be able to improve prognostication for patients with bladder cancer above and beyond grade and stage, but a combination of multiple independent markers might more precisely predict the outcome. From a previous review, we identified seven biomarkers to study within the setting of the Bladder Cancer Prognosis Programme (BCPP), a 5-year multicentre programme of research based at the University of Birmingham and funded by Cancer Research UK, investigating their effectiveness in predicting recurrence and progression. As part of the ongoing quality-assurance process for BCPP we present an updated review of our selected biomarkers, as well as highlighting other recent important developments in bladder cancer research.
引用
收藏
页码:608 / 613
页数:6
相关论文
共 82 条
[71]   Natural history, recurrence, and progression in superficial bladder cancer [J].
Sylvester, Richard J. .
THESCIENTIFICWORLDJOURNAL, 2006, 6 :2617-2625
[72]   FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer [J].
Tomlinson, D. C. ;
Baldo, O. ;
Hamden, P. ;
Knowles, M. A. .
JOURNAL OF PATHOLOGY, 2007, 213 (01) :91-98
[73]   The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder [J].
Touloupidis, Stavros ;
Fatles, Georgios ;
Kalaitzis, Christos ;
Giatromanolaki, Alexandra ;
Sivridis, Eythimyos ;
Simopoulos, Konstantinos ;
Rombis, Vassilios .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2006, 38 (02) :231-236
[74]   Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? [J].
Tsai, Yuh-Shyan ;
Tzai, Tzong-Shin ;
Chow, Nan-Hua .
UROLOGIA INTERNATIONALIS, 2007, 79 (03) :210-216
[75]   A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine [J].
van Oers, JMM ;
Lurkin, I ;
van Exsel, AJA ;
Nijsen, Y ;
van Rhijn, BWG ;
van der Aa, MNM ;
Zwarthoff, EC .
CLINICAL CANCER RESEARCH, 2005, 11 (21) :7743-7748
[76]   FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours [J].
van Oers, Johanna M. M. ;
Wild, Peter J. ;
Buryer, Maximilian ;
Denzinger, Stefan ;
Stoehr, Robert ;
Rosskopf, Elke ;
Hofstaedter, Ferdinand ;
Steyerberg, Ewout W. ;
Klinkhammer-Schalkef, Monika ;
Zwarthoff, Ellen C. ;
van der Kwast, Theodorus H. ;
Hartmann, Arndt .
EUROPEAN UROLOGY, 2007, 52 (03) :760-768
[77]  
Villares GJ, 2007, WORLD J UROL, V25, P573, DOI 10.1007/s00345-007-0202-7
[78]   Molecular markers for detection, surveillance and prognostication of bladder cancer [J].
Vrooman, Olaf P. J. ;
Witjes, J. Alfred .
INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (03) :234-243
[79]   Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways [J].
Wallerand, Herve ;
Reiter, Robert R. ;
Ravaud, Alain .
CURRENT OPINION IN UROLOGY, 2008, 18 (05) :524-532
[80]   Molecular targets and targeted therapies in bladder cancer management [J].
Youssef, Ramy F. ;
Mitra, Anirban P. ;
Bartsch, Georg, Jr. ;
Jones, Peter A. ;
Skinner, Donald G. ;
Cote, Richard J. .
WORLD JOURNAL OF UROLOGY, 2009, 27 (01) :9-20